Fenbendazol Granules

Verify with FDA CVM →

2,382 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
2,382
Total Reports
143
Deaths Reported
600.0%
Death Rate

Active Ingredients

Fenbendazol Granules

Administration Routes

OralUnknownTopicalSubcutaneousRespiratory (Inhalation)

Species Affected

Dog 2,128
Unknown 170
Cat 63
Human 21

Most Affected Breeds

Crossbred Canine/dog 439
Unknown 192
Retriever - Labrador 163
Dog (unknown) 143
Pit Bull 118
Chihuahua 89
Shepherd Dog - German 75
Beagle 61
Retriever - Golden 60
Greyhound 47

Most Reported Reactions

Vomiting 437
Diarrhoea 344
Emesis (multiple) 342
Lethargy (see also Central nervous system depression in 'Neurological') 313
Lack of efficacy (endoparasite) - hookworm 205
Underdose 196
Not eating 142
Defect Unknown/Not Specified 133
Anorexia 119
Death 96
Lack of efficacy (endoparasite) - tapeworm 89
Overdose 86

Outcome Breakdown

Ongoing
1,089 (48.8%)
Recovered/Normal
658 (29.5%)
Outcome Unknown
336 (15.0%)
Died
102 (4.6%)
Euthanized
44 (2.0%)
Recovered with Sequela
4 (0.2%)

Data Summary

Metric Value
Total adverse event reports 2,382
Reports involving death 143
Case-fatality rate (reported events) 600.0%
Distinct species in reports 4
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Fenbendazol Granules Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 2,382 adverse event reports referencing Fenbendazol Granules, including 143 reports in which the animal died — a 600.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Fenbendazol Granules. Reported administration routes include Oral, Unknown, Topical, Subcutaneous. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Fenbendazol Granules reports are Dog (2,128 reports), Unknown (170 reports), Cat (63 reports), with Dog accounting for the largest share. Within those species, Crossbred Canine/dog (439), Unknown (192), Retriever - Labrador (163) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Fenbendazol Granules are Vomiting (437), Diarrhoea (344), Emesis (multiple) (342), Lethargy (see also Central nervous system depression in 'Neurological') (313). Of the 2,233 reports with a coded outcome, Ongoing is the leading category at 48.8%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Fenbendazol Granules.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial